TARGETING ABCB5 FOR CANCER THERAPY
First Claim
Patent Images
1. A method of delivering a therapeutic agent to an intracellular compartment of a cell, comprising:
- contacting a cell with an isolated molecule that selectively binds to ABCB5 conjugated to a therapeutic agent in an effective amount to deliver the therapeutic agent to an intracellular compartment of the cell.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.
-
Citations
64 Claims
-
1. A method of delivering a therapeutic agent to an intracellular compartment of a cell, comprising:
contacting a cell with an isolated molecule that selectively binds to ABCB5 conjugated to a therapeutic agent in an effective amount to deliver the therapeutic agent to an intracellular compartment of the cell. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
10. A composition, comprising
an isolated peptide that selectively binds to ABCB5 and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: - 1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, SEQ ID NO;
6, SEQ ID NO;
7, and SEQ ID NO;
8, or functionally equivalent variants thereof containing conservative substitutions, wherein the isolated peptide is not mAb 3C2-1D12. - View Dependent Claims (17, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)
- 1, SEQ ID NO;
-
11. A composition, comprising
an isolated peptide that selectively binds to ABCB5 and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: - 1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, SEQ ID NO;
6, SEQ ID NO;
7 and SEQ ID NO;
8, or functionally equivalent variants thereof containing conservative substitutions, wherein the isolated peptide is present in an effective amount for enhancing chemosensitization in a human subject.
- 1, SEQ ID NO;
-
12. A composition, comprising
an isolated peptide that selectively binds to ABCB5 and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: - 1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, SEQ ID NO;
6, SEQ ID NO;
7 and SEQ ID NO;
8, or functionally equivalent variants thereof containing conservative substitutions, wherein the isolated peptide is co-formulated with a therapeutic agent. - View Dependent Claims (13, 14)
- 1, SEQ ID NO;
-
15. A kit, comprising
a container housing an isolated peptide that selectively binds to ABCB5 and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: - 1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, SEQ ID NO;
6, SEQ ID NO;
7 and SEQ ID NO;
8, or functionally equivalent variants thereof containing conservative substitutions, and instructions for administering the isolated peptide to a human subject.
- 1, SEQ ID NO;
-
16. A method for treating a subject, comprising
systemically administering an isolated peptide that selectively binds to ABCB5 and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: - 1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, SEQ ID NO;
6, SEQ ID NO;
7, and SEQ ID NO;
8, or functionally equivalent variants thereof containing conservative substitutions to a subject having cancer in an effective amount to treat the cancer.
- 1, SEQ ID NO;
-
18. A method for treating a subject, comprising
administering an isolated peptide that selectively binds to ABCB5 and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: - 1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, SEQ ID NO;
6, SEQ ID NO;
7 and SEQ ID NO;
8, or functionally equivalent variants thereof containing conservative substitutions and a chemotherapeutic agent, to a subject having cancer in an effective amount to treat the cancer.
- 1, SEQ ID NO;
-
19. A method for treating a subject, comprising
systemically administering an isolated antibody or antibody fragment that selectively binds to ABCB5 and a chemotherapeutic agent to a subject having cancer in an effective amount to treat the cancer.
-
20. An isolated peptide comprising an immunoglobulin heavy chain variable domain, wherein:
- (i) CDR1-H1 comprises an amino acid sequence of SEQ ID NO. 3;
(ii) CDR2-H2 comprises an amino acid sequence of SEQ ID NO. 4; and
(iii) a CDR3-H3 sequence, wherein the isolated peptide is not mAb 3C2-1D12. - View Dependent Claims (21, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)
- (i) CDR1-H1 comprises an amino acid sequence of SEQ ID NO. 3;
-
27. An isolated peptide comprising an immunoglobulin light chain variable domain, wherein:
- (i) CDR1-L1 comprises an amino acid sequence of SEQ ID NO. 6;
(ii) CDR2-L2 comprises an amino acid sequence of SEQ ID NO. 7; and
(iii) a CDR3-L3 sequence, wherein the isolated peptide is not mAb 3C2-1D12. - View Dependent Claims (28)
- (i) CDR1-L1 comprises an amino acid sequence of SEQ ID NO. 6;
- 42. An anti-ABCB5 antibody or antigen-binding fragment thereof, having at least one human region, wherein the anti-ABCB5 antibody or antigen binding fragment competitively inhibits binding of mAb 3C2-1D12 to ABCB5.
-
48. A humanized antibody variable domain having a functional antigen binding region, said humanized antibody variable domain comprising non-human CDR1-H1, CDR2-H2, CDR3-H3, CDR1-L1, CD12-L2, and CDR3-L3 having at least 90% homology to CDR1-H1, CDR2-H2, CDR3-H3, CDR1-L1, CDR2-L2, and CDR3-L3 of mAb 3C2-12 incorporated into a human antibody variable domain.
-
49. A chimeric antibody comprising a variable domain which specifically binds to ABCB5 and a constant domain, wherein the variable domain and the constant domain are from different species.
Specification